高级检索
    张少华, 张俊升. 帕博利珠单抗有望改变三阴性晚期乳腺癌一线治疗选择——点评KEYNOTE-355临床研究[J]. 循证医学, 2021, 21(2): 76-78. DOI: 10.12019/j.issn.1671-5144.2021.02.003
    引用本文: 张少华, 张俊升. 帕博利珠单抗有望改变三阴性晚期乳腺癌一线治疗选择——点评KEYNOTE-355临床研究[J]. 循证医学, 2021, 21(2): 76-78. DOI: 10.12019/j.issn.1671-5144.2021.02.003
    shu
    ZHANG Shao-hua, ZHANG Jun-sheng. Pambrolizumab Is Expected to Change the Choice of First-Line Treatment for Advanced Triple-Negative Breast Cancer: Review the KEYNOTE-355 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 76-78. DOI: 10.12019/j.issn.1671-5144.2021.02.003
    Citation: ZHANG Shao-hua, ZHANG Jun-sheng. Pambrolizumab Is Expected to Change the Choice of First-Line Treatment for Advanced Triple-Negative Breast Cancer: Review the KEYNOTE-355 Study[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 76-78. DOI: 10.12019/j.issn.1671-5144.2021.02.003
    shu

    帕博利珠单抗有望改变三阴性晚期乳腺癌一线治疗选择——点评KEYNOTE-355临床研究

    Pambrolizumab Is Expected to Change the Choice of First-Line Treatment for Advanced Triple-Negative Breast Cancer: Review the KEYNOTE-355 Study

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回